Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2175-2182

  Haas, David W ^a   Kwara, Awewura ^b   Richardson, Danielle M ^a   Baker, Paxton ^a   Papageorgiou, Ioannis ^c   Acosta, Edward P ^d   Morse, Gene D ^e   Court, Michael H ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antiretroviral therapy; Non nucleoside reverse transcriptase inhibitor; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; EFAVIRENZ; GLUTATHIONE TRANSFERASE M1; SULFOTRANSFERASE 1A1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2A6 PROTEIN, HUMAN; CYTOCHROME P450 2B6 INDUCER; GLUCURONOSYLTRANSFERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UGT2B7 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BLACK PERSON; CAUCASIAN; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HETEROZYGOSITY; HISPANIC; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SECONDARY METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENE DOSAGE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PROSPECTIVE STUDY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; BENZOXAZINES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2B6 INDUCERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DOSAGE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SECONDARY METABOLISM;

EID: 84904581820     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku110     Document Type: Article

References (50)

1. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Updated February 12, 2013 (8 January 2014, date last accessed).
2. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
3. Gulick RM, Ribaudo HJ, Shikuma CM et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769-81.
4. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
5. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
6. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
7. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
8. Ward BA, Gorski JC, Jones DR et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
9. Desta Z, Saussele T, Ward B et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007; 8: 547-58.
10. Belanger AS, Caron P, Harvey M et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37: 1793-6.
11. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
12. Tsuchiya K, Gatanaga H, Tachikawa N et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-6.
13. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
14. Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/ or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192: 1931-42.
15. Rodriguez-Novoa S, Barreiro P, Rendon A et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40: 1358-61.
16. Holzinger ER, Grady B, Ritchie MD et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012; 22: 858-67.
17. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
18. Wang J, Sonnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16: 191-8.
19. Ribaudo HJ, Liu H, SchwabM et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202: 717-22.
20. NCBI. dbSNP: Short Genetic Variations. http://www.ncbi.nlm.nih.gov/ projects/SNP/ (9 December 2011, date last accessed).
21. Barrett JS, Joshi AS, Chai M et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40: 507-19.
22. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81: 557-66.
23. Rotger M, Saumoy M, Zhang K et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17: 885-90.
24. di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19: 300-9.
25. Kwara A, Lartey M, Sagoe KW et al. CYP2B6 (c.516G_T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67: 427-36.
26. Cortes CP, Siccardi M, Chaikan A et al. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit 2013; 35: 78-83.
27. Swart M, Whitehorn H, Ren Y et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012; 13: 112.
28. Kwara A, LarteyM, SagoeKWet al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23: 2101-6.
29. Sarfo FS, Zhang Y, Egan D et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014; 69; 491-9.
30. Robbins GK, DeGruttola V, Shafer RW et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293-303.
31. Clifford DB, Evans S, Yang Y et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-21.
32. Haas DW, Wilkinson GR, Kuritzkes DR et al. A multi-investigator/ institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003; 4: 287-300.
33. Kwara A, Lartey M, Boamah I et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 2009; 49: 1079-90.
34. Turner ML, Reed-Walker K, King JR et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 331-41.
35. Kwara A, Lartey M, Sagoe KW et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008; 48: 1032-40.
36. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
37. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, 2013.
38. Nunoya K, Yokoi T, Kimura K et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8: 239-49.
39. Fukami T, Nakajima M, Yoshida R et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004; 76: 519-27.
40. Pitarque M, von Richter O, Oke B et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284: 455-60.
41. Yoshida R, Nakajima M, Nishimura K et al. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76.
42. Cho DY, Ogburn ET, Jones D et al. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother 2011; 55: 1504-9.
43. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
44. Gutierrez F, Navarro A, Padilla S et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41: 1648-53.
45. Read TR, Carey D, Mallon P et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 2009; 23: 2222-3.
46. Takahashi M, Ibe S, KudakaY et al. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res Hum Retroviruses 2007; 23: 983-7.
47. Fumaz CR, Munoz-Moreno JA, Molto J et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38: 560-5.
48. Lubomirov R, Colombo S, di Iulio J et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203: 246-57.
49. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45: 1230-7.
50. Puls R, Group tES. A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. In: Abstracts of the Seventh IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 2013. Abstract WELBB01.